RAEB
MCID: MYL074
MIFTS: 33

Myelodysplastic Syndrome with Excess Blasts (RAEB)

Categories: Blood diseases, Rare diseases

Aliases & Classifications for Myelodysplastic Syndrome with Excess Blasts

MalaCards integrated aliases for Myelodysplastic Syndrome with Excess Blasts:

Name: Myelodysplastic Syndrome with Excess Blasts 54
Refractory Anemia with Excess Blasts 54 60 17
Raeb 54

Characteristics:

Orphanet epidemiological data:

60
refractory anemia with excess blasts
Inheritance: Not applicable; Age of onset: Adult;

Classifications:



External Ids:

MESH via Orphanet 46 D000754
ICD10 via Orphanet 35 D46.2
UMLS via Orphanet 75 C0002894
Orphanet 60 ORPHA86839

Summaries for Myelodysplastic Syndrome with Excess Blasts

NIH Rare Diseases : 54 Myelodysplastic syndrome with excess blasts is a rare type of myelodysplastic syndrome (MDS). In this type of MDS, the number of very early forms of blood cells (blasts) are increased in the bone marrow and/or blood. There is also a low numbers of at least one type of blood cell. The early forms of cell types in the bone marrow (red blood cells, white blood cells, or platelets) may or may not look abnormal (dysplasia) under the microscope. Signs and symptoms may include a very hard to treat and persistent anemia (refractory anemia), frequent infections (due to low numbers of neutrophils), easy bruising and bleeding (due to low number or abnormal platelets). MDS with excess blasts is one of the MDS most likely to turn into acute myeloid leukemia (AML). It is classified into 2 types, based on how many of the cells in the bone marrow or blood are blasts:MDS-EB1: blasts make up 5% to 9% of the cells in the bone marrow, or 2% to 4% of the cells in the blood  MDS-EB2: blasts make up 10% to 19% of the cells in the bone marrow, or 5% to 19% of the cells in the blood; this type has a higher risk to become AML. Some cases of MDS are linked to known risk factors (such as smoking, chemotherapy, having a genetic syndrome that increases the chance of developing MDS and other). These factors lead to changes in the DNA in bone marrow cells may cause MDS to develop, but most often, the cause is unknown. Treatment may include blood transfusions, supportive care, chemotherapy, radiotherapy and bone marrow transplant.[ 14773]

MalaCards based summary : Myelodysplastic Syndrome with Excess Blasts, also known as refractory anemia with excess blasts, is related to aplastic anemia and refractory anemia with excess blasts type 2. An important gene associated with Myelodysplastic Syndrome with Excess Blasts is TET2 (Tet Methylcytosine Dioxygenase 2). The drugs Fludarabine and Etoposide have been mentioned in the context of this disorder. Affiliated tissues include myeloid, bone and bone marrow, and related phenotype is liver/biliary system.

Related Diseases for Myelodysplastic Syndrome with Excess Blasts

Graphical network of the top 20 diseases related to Myelodysplastic Syndrome with Excess Blasts:



Diseases related to Myelodysplastic Syndrome with Excess Blasts

Symptoms & Phenotypes for Myelodysplastic Syndrome with Excess Blasts

MGI Mouse Phenotypes related to Myelodysplastic Syndrome with Excess Blasts:

47
# Description MGI Source Accession Score Top Affiliating Genes
1 liver/biliary system MP:0005370 8.62 LTA TET2

Drugs & Therapeutics for Myelodysplastic Syndrome with Excess Blasts

Drugs for Myelodysplastic Syndrome with Excess Blasts (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 239)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Fludarabine Approved Phase 2, Phase 3,Phase 3,Phase 1,Not Applicable 75607-67-9, 21679-14-1 30751
2
Etoposide Approved Phase 2, Phase 3,Phase 3,Phase 1 33419-42-0 36462
3
Cytarabine Approved, Experimental, Investigational Phase 2, Phase 3,Phase 3,Phase 1,Not Applicable 147-94-4, 65-46-3 6253
4
Daunorubicin Approved Phase 2, Phase 3,Phase 3,Phase 1 20830-81-3 30323
5
Idarubicin Approved Phase 2, Phase 3,Phase 3,Phase 1,Not Applicable 58957-92-9 42890
6
Sargramostim Approved, Investigational Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 123774-72-1, 83869-56-1
7
Lenograstim Approved, Investigational Phase 3,Phase 2,Phase 1,Not Applicable 135968-09-1
8
Darbepoetin alfa Approved, Investigational Phase 3,Phase 2 11096-26-7, 209810-58-2
9
Mitoxantrone Approved, Investigational Phase 3,Phase 2,Phase 1,Not Applicable 65271-80-9 4212
10
Decitabine Approved, Investigational Phase 3,Phase 2,Phase 1 2353-33-5 451668
11
Dexamethasone acetate Approved, Investigational, Vet_approved Phase 3,Phase 2 1177-87-3
12
Dexamethasone Approved, Investigational, Vet_approved Phase 3,Phase 2 50-02-2 5743
13
Methylprednisolone Approved, Vet_approved Phase 2, Phase 3,Phase 3,Phase 1,Not Applicable 83-43-2 6741
14
Methylprednisolone hemisuccinate Approved Phase 2, Phase 3,Phase 3,Phase 1,Not Applicable 2921-57-5
15
Prednisolone phosphate Approved, Vet_approved Phase 2, Phase 3,Phase 3,Phase 1,Not Applicable 302-25-0
16
Prednisolone Approved, Vet_approved Phase 2, Phase 3,Phase 3,Phase 1,Not Applicable 50-24-8 5755
17
Arsenic trioxide Approved, Investigational Phase 2, Phase 3,Phase 1 1327-53-3 518740
18
Thiotepa Approved, Investigational Phase 2, Phase 3,Phase 1 52-24-4 5453
19
Cyclophosphamide Approved, Investigational Phase 3,Phase 2,Phase 1,Not Applicable 6055-19-2, 50-18-0 2907
20
Thioguanine Approved Phase 3 154-42-7 2723601
21
Hydrocortisone acetate Approved, Vet_approved Phase 3 50-03-3
22
Methotrexate Approved Phase 3,Phase 2,Phase 1,Not Applicable 1959-05-2, 59-05-2 126941
23
Hydrocortisone Approved, Vet_approved Phase 3 50-23-7 5754
24
Busulfan Approved, Investigational Phase 3,Phase 2,Phase 1,Not Applicable 55-98-1 2478
25
Aldesleukin Approved Phase 3,Phase 1,Phase 2 85898-30-2, 110942-02-4
26
leucovorin Approved Phase 3,Phase 2,Phase 1,Not Applicable 58-05-9 6006 143
27
Miconazole Approved, Investigational, Vet_approved Phase 3,Phase 2,Phase 1,Not Applicable 22916-47-8 4189
28
Amsacrine Approved, Investigational Phase 3 51264-14-3 2179
29
Tacrolimus Approved, Investigational Phase 2, Phase 3,Phase 1,Not Applicable 104987-11-3 445643 439492 6473866
30
Hydroxyurea Approved Phase 3 127-07-1 3657
31
Melphalan Approved Phase 2, Phase 3,Phase 3,Phase 1,Not Applicable 148-82-3 460612 4053
32
alemtuzumab Approved, Investigational Phase 2, Phase 3,Phase 1 216503-57-0
33
Azacitidine Approved, Investigational Phase 2, Phase 3,Phase 3,Phase 1,Not Applicable 320-67-2 9444
34
Clofarabine Approved, Investigational Phase 2, Phase 3 123318-82-1 119182
35
Carboplatin Approved Phase 2, Phase 3,Phase 1 41575-94-4 38904 10339178 498142
36
Ivosidenib Approved, Investigational Phase 3 1448347-49-6
37
midostaurin Approved, Investigational Phase 2, Phase 3 120685-11-2 9829523 104937
38
Coal tar Approved Phase 2, Phase 3 8007-45-2
39
nivolumab Approved Phase 2, Phase 3 946414-94-4
40
Folic Acid Approved, Nutraceutical, Vet_approved Phase 3,Phase 2,Phase 1,Not Applicable 59-30-3 6037
41
Tretinoin Approved, Investigational, Nutraceutical Phase 3,Phase 1,Phase 2 302-79-4 5538 444795
42
Glycine Approved, Nutraceutical, Vet_approved Phase 3 56-40-6 750
43
Prednisolone hemisuccinate Experimental Phase 2, Phase 3,Phase 3,Phase 1,Not Applicable 2920-86-7
44
tipifarnib Investigational Phase 3,Phase 2,Phase 1 192185-72-1 159324
45 Staurosporine Experimental Phase 2, Phase 3,Phase 1 62996-74-1
46 Anti-Bacterial Agents Phase 2, Phase 3,Phase 3,Phase 1,Not Applicable
47 Antiviral Agents Phase 2, Phase 3,Phase 3,Phase 1,Not Applicable
48 Antimetabolites Phase 2, Phase 3,Phase 3,Phase 1,Not Applicable
49 Etoposide phosphate Phase 2, Phase 3,Phase 3,Phase 1
50 Anti-Infective Agents Phase 2, Phase 3,Phase 3,Phase 1,Not Applicable

Interventional clinical trials:

(show top 50) (show all 197)
# Name Status NCT ID Phase Drugs
1 Treatment of Adults Aged Up to 60 Years With De Novo Acute Myeloblastic Leukaemia,Secondary AML, or RAEB-T Unknown status NCT00209833 Phase 2, Phase 3 Cytarabine;Idarubicin;Etoposide;Fludarabine;G-CSF;Daunorubicine
2 Comparison Study of Standard Care Against Combination of Growth Factors Agents for Low-risk Myelodysplastic Syndromes Unknown status NCT01196715 Phase 3 Darbepoetin alpha;Filgrastim
3 Erythropoietin (EPO) and Granulocyte-Colony Stimulating Factor (G-CSF) for Low-Risk Myelodysplastic Syndromes (MDS) Unknown status NCT00234143 Phase 2, Phase 3 Darbepoetin
4 Combination Chemotherapy in Treating Older Patients With Acute Myeloid Leukemia Unknown status NCT00003602 Phase 3 cytarabine;etoposide;idarubicin;mitoxantrone hydrochloride
5 Combination Chemotherapy With or Without Peripheral Stem Cell Transplantation in Treating Patients With Myelodysplastic Syndrome or Acute Myelogenous Leukemia Unknown status NCT00002926 Phase 3 cytarabine;etoposide;idarubicin
6 Low-Dose Decitabine Compared With Standard Supportive Care in Treating Older Patients With Myelodysplastic Syndrome Unknown status NCT00043134 Phase 3 decitabine
7 Cytarabine and Daunorubicin With or Without Gemtuzumab Ozogamicin in Treating Older Patients With Acute Myeloid Leukemia or Myelodysplastic Syndromes Completed NCT00121303 Phase 3 cytarabine;daunorubicin hydrochloride;gemtuzumab ozogamicin
8 Daunorubicin & Cytarabine +/- Zosuquidar inTreating Older Patients With Newly Diagnosed Acute Myeloid Leukemia or Refractory Anemia Completed NCT00046930 Phase 3 cytarabine;daunorubicin hydrochloride;zosuquidar trihydrochloride;Placebo
9 Combination Chemotherapy With or Without Bone Marrow Transplantation in Treating Children With Acute Myelogenous Leukemia or Myelodysplastic Syndrome Completed NCT00002798 Phase 3 asparaginase;daunorubicin hydrochloride;fludarabine phosphate;therapeutic hydrocortisone;cytarabine;idarubicin;dexamethasone;thioguanine;etoposide;methotrexate;cyclophosphamide;busulfan
10 Tipifarnib in Treating Patients With Acute Myeloid Leukemia in Remission Completed NCT00093470 Phase 3 Tipifarnib
11 S9920 Busulfan Compared With Cyclophosphamide in Patients Undergoing Total-Body Irradiation Plus Peripheral Stem Cell Transplantation for Advanced Myelodysplastic Syndrome or Related Acute Myeloid Leukemia Completed NCT00005866 Phase 3 busulfan;cyclophosphamide;cyclosporine;methotrexate
12 Combination Chemotherapy With or Without Bone Marrow Transplantation in Treating Children With Acute Myeloid Leukemia Completed NCT00003436 Phase 3 amsacrine;asparaginase;cytarabine;daunorubicin hydrochloride;etoposide;methotrexate;mitoxantrone hydrochloride;therapeutic hydrocortisone
13 Sibling Donor Peripheral Stem Cell Transplant or Sibling Donor Bone Marrow Transplant in Treating Patients With Hematologic Cancers or Other Diseases Completed NCT00438958 Phase 3
14 Bone Marrow Transplantation in Treating Patients With Leukemia, Myelodysplasia, or Lymphoblastic Lymphoma Completed NCT00003187 Phase 2, Phase 3 cyclophosphamide;cyclosporine;cytarabine;methotrexate;methylprednisolone
15 Treatment of Bone Marrow to Prevent Graft-Versus-Host Disease in Patients With Acute or Chronic Leukemia Undergoing Bone Marrow Transplantation Completed NCT00004255 Phase 2, Phase 3 cyclophosphamide;fludarabine phosphate;methylprednisolone;tacrolimus
16 Intensive Compared With Nonintensive Chemotherapy in Treating Older Patients With Acute Myeloid Leukemia or Myelodysplastic Syndrome Completed NCT00005823 Phase 3 cytarabine;daunorubicin hydrochloride;etoposide;hydroxyurea;idarubicin;mitoxantrone hydrochloride;thioguanine;tretinoin;valspodar
17 Chemotherapy in Treating Children With Down Syndrome and Myeloproliferative Disorder, Acute Myelogenous Leukemia, or Myelodysplastic Syndrome Completed NCT00003593 Phase 3 asparaginase;cytarabine;daunorubicin hydrochloride;methotrexate;therapeutic hydrocortisone;thioguanine
18 Combination Chemotherapy in Treating Children With Newly Diagnosed Acute Myeloid Leukemia or Myelodysplastic Syndrome Completed NCT00002517 Phase 3 cytarabine;daunorubicin hydrochloride;dexamethasone;etoposide;idarubicin;mitoxantrone hydrochloride;thioguanine
19 Antithymocyte Globulin and Cyclosporine in Treating Patients With Myelodysplastic Syndrome Completed NCT00004208 Phase 3 ATG + CSA
20 Combination Chemotherapy With or Without Gemtuzumab Ozogamicin or Tipifarnib in Treating Patients With Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndromes Completed NCT00454480 Phase 2, Phase 3 arsenic trioxide;azacitidine;busulfan;clofarabine;cytarabine;daunorubicin hydrochloride;fludarabine phosphate;gemtuzumab ozogamicin;melphalan;tipifarnib
21 G-CSF+Decitabine+BUCY vs BUCY Conditioning Regimen for RAEB-1, REAB-2 and AML Secondary to MDS Undergoing Allo-HSCT Recruiting NCT02744742 Phase 2, Phase 3 Decitabine;Busulfan (BU);Cyclophosphamide (CY);Granulocyte Colony-Stimulating Factor(G-CSF)
22 Controlled Study of Rigosertib Versus Physician's Choice of Treatment in MDS Patients After Failure of an HMA Recruiting NCT02562443 Phase 3 rigosertib;Any approved or standard-of-care therapy;best supportive care (BSC);best supportive care (BSC)
23 Efficacy and Safety of IV Rigosertib in MDS Patients With Excess Blasts Progressing After Azacitidine or Decitabine Active, not recruiting NCT01928537 Phase 3 rigosertib sodium
24 Combination Chemotherapy and Donor Stem Cell Transplant in Treating Patients With Aplastic Anemia or Hematologic Cancer Active, not recruiting NCT00003816 Phase 2, Phase 3 busulfan;carboplatin;cyclophosphamide;etoposide;fludarabine phosphate;melphalan;thiotepa
25 A Study of Ivosidenib or Enasidenib in Combination With Induction Therapy and Consolidation Therapy, Followed by Maintenance Therapy in Patients With Newly Diagnosed Acute Myeloid Leukemia or Myedysplastic Syndrome EB2, With an IDH1 or IDH2 Mutation, Respectively, Eligible for Intensive Chemotherapy Not yet recruiting NCT03839771 Phase 3 AG-120;Placebo for AG-120;AG-221;Placebo for AG-221
26 Azacitidine With or Without Nivolumab or Midostaurin, or Decitabine and Cytarabine Alone in Treating Older Patients With Newly Diagnosed Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome Suspended NCT03092674 Phase 2, Phase 3 Azacitidine;Cytarabine;Decitabine;Midostaurin
27 A Randomized Study of Post-Remission Therapy in Elderly Patients With Acute Myelogenous Leukemia. Terminated NCT00363025 Phase 3 Idarubicin versus daunorubicin
28 Amifostine in Treating Patients With Advanced Myelodysplastic Syndrome Unknown status NCT00003123 Phase 2 amifostine trihydrate
29 Antithymocyte Globulin Compared With Supportive Care in Treating Patients With Myelodysplastic Syndrome Unknown status NCT00017550 Phase 2
30 Combination Chemotherapy in Treating Patients With Myelodysplastic Syndrome Unknown status NCT00003827 Phase 2 amifostine trihydrate;cytarabine;topotecan hydrochloride
31 Gemtuzumab in Treating Patients With Myelodysplastic Syndrome Unknown status NCT00022321 Phase 2 gemtuzumab ozogamicin
32 Arsenic Trioxide in Treating Patients With Myelodysplastic Syndromes Unknown status NCT00020969 Phase 2 arsenic trioxide
33 Vaccine Therapy and GM-CSF in Treating Patients With Low-Risk or Intermediate-Risk Myelodysplastic Syndrome Unknown status NCT00513578 Phase 2
34 Amifostine With or Without Epoetin Alfa in Treating Patients With Myelodysplastic Syndrome Unknown status NCT00003681 Phase 2 amifostine trihydrate
35 Amifostine and High-Dose Combination Chemotherapy in Treating Patients With Acute Myeloid Leukemia or Chronic Myelogenous Leukemia Unknown status NCT00003407 Phase 2 amifostine trihydrate;cytarabine;mitoxantrone hydrochloride
36 Study of 72-Hour Infusion of ON 01910.Na in Patients With MDS or AML Completed NCT00854945 Phase 1, Phase 2 ON 01910.Na
37 Liposomal Daunorubicin and SU5416 in Treating Patients With Hematologic Cancer That Has Not Responded to Initial Therapy Completed NCT00005942 Phase 1, Phase 2 liposomal daunorubicin citrate;semaxanib
38 Amifostine Plus Topotecan in Treating Patients With Myelodysplastic Syndrome Completed NCT00003415 Phase 1, Phase 2 amifostine trihydrate;topotecan hydrochloride
39 Infusion of Off-the-Shelf Expanded Cord Blood Cells to Augment Cord Blood Transplant in Patients With Hematologic Malignancies Completed NCT01175785 Phase 2 fludarabine phosphate;cyclophosphamide;cyclosporine;mycophenolate mofetil
40 Thalidomide in Treating Patients With Myelodysplastic Syndrome Completed NCT00015990 Phase 2 thalidomide
41 Vaccine Therapy Plus Immune Adjuvant in Treating Patients With Chronic Myeloid Leukemia, Acute Myeloid Leukemia, or Myelodysplastic Syndrome Completed NCT00004918 Phase 1, Phase 2 Montanide ISA 51 VG
42 Idarubicin, Cytarabine, and Tipifarnib in Treating Patients With Newly Diagnosed Myelodysplastic Syndromes or Acute Myeloid Leukemia Completed NCT00096122 Phase 1, Phase 2 cytarabine;idarubicin;tipifarnib
43 CCI-779 in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, Myelodysplastic Syndromes, or Chronic Myelogenous Leukemia in Blastic Phase Completed NCT00084916 Phase 2 temsirolimus
44 Biological Therapy in Treating Patients With Advanced Myelodysplastic Syndrome, Acute or Chronic Myeloid Leukemia, or Acute Lymphoblastic Leukemia Who Are Undergoing Stem Cell Transplantation Completed NCT00052520 Phase 1, Phase 2
45 Safety and Tolerability Trial of Abatacept-based Immunosuppression for Prevention of Acute GvHD During Unrelated Donor Hematopoietic Stem Cell Transplant Completed NCT01012492 Phase 2 Abatacept
46 Lenalidomide and Azacitidine in Treating Patients With Advanced Myelodysplastic Syndromes Completed NCT00352001 Phase 1, Phase 2 azacitidine;lenalidomide
47 Differentiation Therapy With Decitabine in Treating Patients With Myelodysplastic Syndrome Completed NCT01165996 Phase 1, Phase 2 decitabine
48 Vorinostat, Tacrolimus, and Methotrexate in Preventing GVHD After Stem Cell Transplant in Patients With Hematological Malignancies Completed NCT01789255 Phase 2 vorinostat;tacrolimus;cyclosporine;methotrexate
49 Arsenic Trioxide and Gemtuzumab Ozogamicin in Treating Patients With Advanced Myelodysplastic Syndromes Completed NCT00274781 Phase 2 arsenic trioxide;gemtuzumab ozogamicin
50 Sargramostim After Bone Marrow Transplantation in Treating Patients With Myelodysplastic Syndrome Completed NCT00003961 Phase 2

Search NIH Clinical Center for Myelodysplastic Syndrome with Excess Blasts

Genetic Tests for Myelodysplastic Syndrome with Excess Blasts

Anatomical Context for Myelodysplastic Syndrome with Excess Blasts

MalaCards organs/tissues related to Myelodysplastic Syndrome with Excess Blasts:

42
Myeloid, Bone, Bone Marrow, T Cells, Neutrophil, Kidney, Breast

Publications for Myelodysplastic Syndrome with Excess Blasts

Articles related to Myelodysplastic Syndrome with Excess Blasts:

(show all 50)
# Title Authors Year
1
[Clinical Efficacy of Low-dose Decitabine Combined with CAG Regimen in Patients with Myelodysplastic Syndrome-refractory Anemia with Excess Blasts(MDS-RAEB)]. ( 29070129 )
2017
2
Myelodysplastic syndrome with excess blasts-2 associated with erythroid predominance. ( 28209754 )
2017
3
Modest improvement in survival of patients with refractory anemia with excess blasts in the hypomethylating agents era in the United States. ( 27558206 )
2016
4
Acute erythroid leukemia with <20% bone marrow blasts is clinically and biologically similar to myelodysplastic syndrome with excess blasts. ( 27443511 )
2016
5
Low Dose Cytosine Arabinoside and Azacitidine Combination in Elderly Patients with Acute Myeloid Leukemia and Refractory Anemia with Excess Blasts (MDS-RAEB2). ( 26855506 )
2016
6
Acquired elliptocytosis in the setting of a refractory anemia with excess blasts and del(20q). ( 28092889 )
2016
7
Myeloid Sarcoma of the Bladder in the Setting of Refractory Anemia with Excess Blasts-2 (RAEB-2). ( 26665895 )
2015
8
Isolated trisomy 13 in refractory anemia with excess blasts: report of two cases and a brief literature review of this possible association. ( 26133721 )
2015
9
Decitabine versus best supportive care in older patients with refractory anemia with excess blasts in transformation (RAEBt) - results of a subgroup analysis of the randomized phase III study 06011 of the EORTC Leukemia Cooperative Group and German MDS Study Group (GMDSSG). ( 26400023 )
2015
10
+ 252A/G polymorphism in lymphotoxin-I+ gene influences long-term survival in patients with myelodysplastic syndrome with excess blasts. ( 23931336 )
2014
11
Proteome changes in the plasma of myelodysplastic syndrome patients with refractory anemia with excess blasts subtype 2. ( 24958999 )
2014
12
A phase I trial of vorinostat and alvocidib in patients with relapsed, refractory, or poor prognosis acute leukemia, or refractory anemia with excess blasts-2. ( 23515411 )
2013
13
Pathogenetic role of ETV6 fusion gene in leukemic transformation of myelodysplastic syndrome refractory anemia with excess blasts-1 with a new, rare translocation t(11;19)(q24.3;q13.12) and insertion ins(6;12)(p22.3p13). ( 23772667 )
2013
14
Plasma protein alterations in the refractory anemia with excess blasts subtype 1 subgroup of myelodysplastic syndrome. ( 22568928 )
2012
15
FLAGIDA-lite is an effective regimen for patients between 70 and 80 years with acute myeloid leukemia or refractory anemia with excess blasts-2 and is feasible as outpatient treatment. ( 22015963 )
2012
16
Huge multinucleated megaloblasts found in a patient with refractory anemia with excess blasts-1. ( 23099925 )
2012
17
Immunologic characteristics and prognosis of myelodysplastic syndrome new subtype: refractory anemia with excess blasts-II. ( 19236759 )
2009
18
Chronic myelomonocytic leukemia with antecedent refractory anemia with excess blasts: further evidence for the arbitrary nature of current classification systems. ( 18604717 )
2008
19
Donor lymphocyte infusions for post-transplant relapse of refractory anemia with excess blasts and monosomy 7. ( 17253642 )
2008
20
Copper deficiency with increased hematogones mimicking refractory anemia with excess blasts. ( 17706281 )
2008
21
An antecedent diagnosis of refractory anemia with excess blasts has no influence on mobilization of peripheral blood stem cells and hematopoietic recovery after autologous stem cell transplantation in acute myeloid leukemia. ( 17042770 )
2007
22
An antecedent diagnosis of refractory anemia with excess blasts has no prognostic relevance in acute myeloid leukemia of older adult patients. ( 16687417 )
2006
23
Independent prognostic significance of day 21 cytogenetic findings in newly-diagnosed acute myeloid leukemia or refractory anemia with excess blasts. ( 12857550 )
2003
24
A cytochemical note on nucleoli of granulocytic precursors and granulocytes in patients suffering from the refractory anemia with excess blasts (RAEB) of the myelodysplastic syndrome (MDS). ( 12044061 )
2002
25
More cell death in refractory anemia with excess blasts in transformation than in acute myeloid leukemia. ( 12399969 )
2002
26
HIV and refractory anemia with excess blasts (RAEB). ( 12210814 )
2002
27
Re-evaluation of refractory anemia with excess blasts in transformation. ( 11597728 )
2001
28
Comparison of idarubicin + ara-C-, fludarabine + ara-C-, and topotecan + ara-C-based regimens in treatment of newly diagnosed acute myeloid leukemia, refractory anemia with excess blasts in transformation, or refractory anemia with excess blasts. ( 11739159 )
2001
29
Differences between refractory anemia with excess blasts in transformation and acute myeloid leukemia. ( 10939804 )
2000
30
Low-dose cytarabine and aclarubicin in combination with granulocyte colony-stimulating factor (CAG regimen) for previously treated patients with relapsed or primary resistant acute myelogenous leukemia (AML) and previously untreated elderly patients with AML, secondary AML, and refractory anemia with excess blasts in transformation. ( 10846828 )
2000
31
Translocation (5;18) in a patient with myelodysplastic syndrome: refractory anemia with excess blasts in transformation. ( 11203251 )
2000
32
5q- in a child with refractory anemia with excess blasts: similarities to 5q- syndrome in adults. ( 9723027 )
1998
33
Severe hypodiploidy in refractory anemia with excess blasts in transformation. ( 9723043 )
1998
34
Effect of diagnosis (refractory anemia with excess blasts, refractory anemia with excess blasts in transformation, or acute myeloid leukemia [AML]) on outcome of AML-type chemotherapy. ( 9376577 )
1997
35
On a dramatic response of refractory anemia with excess blasts in transformation to 5-azacytidine. ( 7539583 )
1995
36
High remission rate, short remission duration in patients with refractory anemia with excess blasts (RAEB) in transformation (RAEB-t) given acute myelogenous leukemia (AML)-type chemotherapy in combination with granulocyte-CSF (G-CSF). ( 9384660 )
1995
37
Lineage-unrestricted hematologic response to granulocyte colony-stimulating factor in a patient with refractory anemia with excess blasts. ( 7536478 )
1995
38
5q- chromosome. Evidence for complex interstitial breaks in a case of refractory anemia with excess blasts. ( 8194054 )
1994
39
Trisomy 8 and 11 in refractory anemia with excess blasts in transformation (RAEB-T). ( 1521244 )
1992
40
Trisomy 14 in refractory anemia with excess blasts in transformation. ( 1555198 )
1992
41
Complex chromosomal abnormalities in a patient with refractory anemia with excess blasts (RAEB). ( 1884355 )
1991
42
Dissociation between In-111 chloride and Tc-99m colloid bone marrow scintigraphy in refractory anemia with excess blasts. ( 2311325 )
1990
43
Effect of recombinant human granulocyte-macrophage colony-stimulating factor in patients with myelodysplastic syndrome with excess blasts. ( 2654495 )
1989
44
Formation of double minutes by breakdown of a homogeneously staining region in a refractory anemia with excess blasts. ( 3395993 )
1988
45
Disturbances of T lymphocyte subsets preceding refractory anemia with excess blasts in transformation in a child. ( 3124467 )
1988
46
Translocation t(6;9)(p22.3;q34) in myelodysplastic syndrome--refractory anemia with excess blasts. ( 3664444 )
1987
47
Duplication of one of the products of the t(8;21) translocation in a patient with refractory anemia with excess blasts in transformation. ( 3802052 )
1987
48
Dysmyelopoiesis in the cat: a hematological disorder resembling refractory anemia with excess blasts in man. ( 3742354 )
1986
49
Multinucleate megakaryocytes in refractory anemia with excess blasts. ( 6687675 )
1983
50
A phase II study of prednimustine in acute non-lymphocytic leukemia, smouldering leukemia, and refractory anemia with excess blasts. ( 7139848 )
1982

Variations for Myelodysplastic Syndrome with Excess Blasts

Expression for Myelodysplastic Syndrome with Excess Blasts

Search GEO for disease gene expression data for Myelodysplastic Syndrome with Excess Blasts.

Pathways for Myelodysplastic Syndrome with Excess Blasts

GO Terms for Myelodysplastic Syndrome with Excess Blasts

Sources for Myelodysplastic Syndrome with Excess Blasts

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
20 FMA
29 GO
30 GTR
31 HGMD
32 HMDB
33 HPO
34 ICD10
35 ICD10 via Orphanet
36 ICD9CM
37 IUPHAR
38 KEGG
39 LifeMap
41 LOVD
43 MedGen
45 MeSH
46 MESH via Orphanet
47 MGI
50 NCI
51 NCIt
52 NDF-RT
55 NINDS
56 Novoseek
58 OMIM
59 OMIM via Orphanet
63 PubMed
65 QIAGEN
70 SNOMED-CT via HPO
71 SNOMED-CT via Orphanet
72 TGDB
73 Tocris
74 UMLS
75 UMLS via Orphanet
Content
Loading form....